Stem Cell Research News ($)
Stem Cell Business News ($)
The Stem Cell Trekker
Subscription Page
It's  

 

 

13th Edition Guide to Stem Cell Research Companies

Complete listing of global companies performing stem cell research... PLUS stem cell research suppliers AND for-profit cord blood banks! 214 companies in all ... Soon  available in a paperback edition.

Click for more information
Stem Cell Primer

27 pages ... PDF ... Everything you need to know about stem cells and stem cell science.

Only $5.00 (limited time offer)

Click here to order ...

How can I access archived ($) content? 

Start a subscription to Stem Cell Research News at the low individual annual rate to access ALL archived content on this Web site. All articles are posted for free access for seven days. Afterward, articles are archived and require a subscription. 

Click for more information

 
FDA Approves First Stem Cell Clinical Trial For Multiple Sclerosis - ($)
Wednesday, September 11, 2013 - Stem Cell Research News - In The Clinic
DoctorPatient.png
 

          NEW YORK, N.Y., August 14, 2013 – The Tisch MS Research Center of New York has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to launch a Phase 1 trial using autologous neural stem cells in the treatment of multiple sclerosis (MS).

MS is a chronic human autoimmune disease of the central nervous system that leads to myelin damage and neurodegeneration and affects approximately 2.1 million people worldwide.

“To my knowledge, this is the first FDA-approved stem cell trial in the United States to investigate direct injection of stem cells into the cerebrospinal fluid of MS patients, and represents an exciting advance in MS research and treatment,” said Dr. Saud A. Sadiq, senior research scientist at Tisch and the study’s principal investigator.

The groundbreaking study will investigate a regenerative strategy using stem cells harvested from the patient’s own bone marrow.

These stem cells will be injected into the cerebrospinal fluid surrounding the spinal cord in 20 participants who meet the inclusion criteria for the trial.

This will be an open label safety and tolerability study. All study activities will be conducted at the Tisch MS Research Center and affiliated International Multiple Sclerosis Management Practice (IMSMP).

The clinical application of autologous neural progenitors in MS is the culmination of a decade of stem cell research conducted by a dedicated team of scientists headed by Sadiq and by Dr. Violaine Harris, research scientist at Tisch.

Preclinical testing found that the injection of these cells may decrease brain inflammation and promote myelin repair and/or neuroprotection.

“This study exemplifies the Tisch MS Research Center’s dedication to translational research and provides a hope that established disability may be reversed in MS,” Sadiq said.

Participants will undergo a single bone marrow collection procedure, from which mesenchymal stem cell-derived neural progenitor cells (MSC-NPs) will be isolated, expanded and tested prior to injection.

They will receive three rounds of injections at three month intervals. Safety and efficacy parameters will be evaluated in all participants through regular follow-up visits.

Contact: http://www.tischms.org


Scroll down to see related articles below. 
 



Related Articles :

E-mail this stem cell article to a friend - Print this stem cell article
Articles can be e-mailed to a friend or you can get a printable version of the article.

 
Search Stem Cell Articles :
Enter key word(s)

 
 
 

 



 
 



 

Copyright © 2003 -  2014 by DataTrends Publications, Inc. All rights reserved.